Mycenax Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	740.24	683.92	652.62	732.28	774.27
Revenue Growth (YoY)	8.23%	4.80%	-10.88%	-5.42%	16.37%
Cost of Revenue	921.65	925.28	1,028	845.95	636.66
Gross Profit	-181.41	-241.36	-375.19	-113.67	137.61
Selling, General & Admin	148.07	141.94	152.23	156.16	133.96
Research & Development	75.91	78.19	75.81	144	96.13
Operating Expenses	222.43	220.18	226.91	331.32	222.94
Operating Income	-403.84	-461.54	-602.1	-445	-85.33
Interest Expense	-33.67	-26.16	-23.46	-15.42	-1.17
Interest & Investment Income	3.12	8.53	17.66	3.8	0.31
Earnings From Equity Investments	-21.13	-12.94	-8.7	-0.76	-
Currency Exchange Gain (Loss)	-	14.58	3.35	13.29	-1.35
Other Non Operating Income (Expenses)	1.41	-4.96	0.75	0.21	-0.11
EBT Excluding Unusual Items	-454.11	-482.5	-612.5	-443.87	-87.65
Gain (Loss) on Sale of Assets	-	-	-	-20.11	0.13
Other Unusual Items	-	1.07	-71.48	1.13	-
Pretax Income	-454.11	-469.59	-683.98	-462.84	-87.52
Income Tax Expense	-5.48	-2.46	-1.13	-9.21	2.34
Net Income	-448.63	-467.13	-682.85	-453.63	-89.86
Net Income to Common	-448.63	-467.13	-682.85	-453.63	-89.86
Shares Outstanding (Basic)	207	206	206	165	148
Shares Outstanding (Diluted)	207	206	206	165	148
Shares Change (YoY)	0.36%	0.23%	24.31%	11.35%	15.36%
EPS (Basic)	-2.17	-2.27	-3.32	-2.74	-0.61
EPS (Diluted)	-2.17	-2.27	-3.32	-2.74	-0.61
Free Cash Flow	-115.78	-522.11	-426.81	-777.12	-1,244
Free Cash Flow Per Share	-0.56	-2.54	-2.08	-4.70	-8.38
Gross Margin	-24.51%	-35.29%	-57.49%	-15.52%	17.77%
Operating Margin	-54.55%	-67.48%	-92.26%	-60.77%	-11.02%
Profit Margin	-60.61%	-68.30%	-104.63%	-61.95%	-11.61%
Free Cash Flow Margin	-15.64%	-76.34%	-65.40%	-106.12%	-160.71%
EBITDA	-119.51	-206.91	-338.27	-219.7	44.33
EBITDA Margin	-16.14%	-30.25%	-51.83%	-30.00%	5.73%
D&A For EBITDA	284.33	254.63	263.83	225.3	129.66
EBIT	-403.84	-461.54	-602.1	-445	-85.33
EBIT Margin	-54.55%	-67.48%	-92.26%	-60.77%	-11.02%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.